Tumor antigens such as Wilm’s tumor (WT1) (Menssen et al. 1995), preferentially expressed antigen of melanoma (PRAME) (Ikeda et al. 1997), proteinase 3 (PRTN3) (Molldrem et al. 1996) and the receptor for hyaluronic acid mediated motility (RHAMM/CD168) (Greiner et al. 2002) have been used with some success in phase I/II clinical trials (Greiner et al. 2005; Guinn et al. 2006b; Heslop et al. 2003; Li et al. 2006; Mailander et al. 2004; Oka et al. 2004) (reviewed elsewhere in Guinn et al. 2006b; Heslop et al. 2003). This evidence concerns the gene PRTN3 and melanoma.